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Background: It has been reported that the survival of hemodialysis (HD) patients is poor, and the leading cause of
death is cardiovascular disease. To identify high-risk patients and treat them carefully, we developed a scoring
system to evaluate their 15-year prognosis in a prospective cohort study.
Methods: We analyzed data from 312 and 310 patients to develop and validate the prediction model, respectively.
The association of potential risk factors with death was tested by Cox proportional-hazards analysis, and a risk
scoring model was developed. Then, the model was validated.
Results: Two hundred patients (64.1 %) in the cohort for model development died. Six independent prognostic factors
were retained in the final model, and each was assigned a score proportional to its regression coefficient: 65 years or
older, 3; diabetic nephropathy, 3; hypotension, 1; pre-HD cardiothoracic ratio ≥50 %, 1; pre-HD BNP ≥250 pg/mL, 1;
and pre-HD numbers of abnormal findings on electrocardiograms = 0, 1, 2, or larger, 0, 1, 5. The patients were
categorized as follows with their scores: group 1 (low risk), 0; group 2, 1 to 3; group 3, 4 to 5; and group 4 (high risk), 6
and higher. In the cohort for model validation, groups 2 to 4 showed a higher risk than group 1: group 2, hazard ratio
4.66 (95 % confidence interval 2.25, 9.64); group 3, 13.62 (6.48, 28.63); and group 4, 20.86 (9.60, 45.31).
Conclusions: A new risk scoring system for predicting 15-year mortality was developed. This system may be useful for
evaluating HD patients’ prognosis.
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Fig. 1 Flow diagram of participants
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The number of patients on maintenance hemodialysis
(HD) has been rapidly increasing over the last decades
[1], and more than 320,000 patients are on maintenance
HD in Japan at the end of 2014 [2]. This phenomenon
has been attributed to the increase in the number of pa-
tients with diabetes (the main cause of renal failure in
Japan) along with the advances in the techniques of HD
and medical therapy for renal failure. However, the poor
survival of dialysis patients has been reported by a num-
ber of investigators [3]. Cardiovascular disease (CVD) is
common among these patients and is the primary cause
of death in this population [4].
There were few papers that reported the impact of car-
diac and/or circulatory disorder parameters, which are
routinely measured along with vital signs during HD
treatment, on long-term prognosis. To evaluate HD patients’
prognosis and find patients with high risk of death, there is
a need for novel index that is based on the cardiac disorder
parameters. We, therefore, conducted a long-term prospect-
ive multicenter cohort study to establish a prediction model
for mortality in maintenance HD patients using not specific
parameters but clinically easy to measure parameters.
Methods
Study design and study population
This study conducted in two medical corporations oper-
ating seven HD clinics and one hospital in total and HD
units of a general hospital in Japan as a multicenter ob-
servational study. The participating facilities were as
follows: Tokiwa-kai Medical Corporation Group (Iwaki
Urological Clinic, Izumi Clinic), Meysey-kai Medical
Corporation Group (Airport Urological Clinic, Yokaichiba
Clinic, Yachimata Clinic, Togane Clinic, Oami Neurosur-
gery Clinic, Mitsuhashi Hospital), and Chiba Social Insur-
ance Hospital (Current name: JCHO Chiba Hospital). This
study was approved by the ethics committees of all partici-
pating institutions (Meysey-kai Medical Corporation Group
No. 215070001, Tokiwa-kai Medical Corporation Group
No. 19-2, JCHO Chiba Hospital No. 45), and the research
was conducted in accordance with the ethical principles of
the Declaration of Helsinki. Informed consent was obtained
by providing a document containing all the required ele-
ments of informed consent that gives patients the option to
provide permission.
All the patients who received maintenance HD in these
sites between October 1997 and April 1999 were enrolled
(Fig. 1). Patients under 20 years, under the treatment of
cancer, and on HD for less than 1 month were excluded.
Patients with missing values and apparent outliers were also
excluded (n = 102). The remaining patients were randomly
classified into two groups to obtain (1) a dataset for the
development of risk score (development dataset) and (2) a
dataset for validation of risk score (validation dataset).Data
The patients’ demographics, namely, age, gender, body
mass index (BMI) calculated on the basis of post-HD body
weight, diabetes mellitus (DM) as a cause of end-stage
renal disease (ESRD), history of CVD, hypertension,
hypotension during HD, pre-HD cardiothoracic ratio
(CTR, %), pre-HD hemoglobin level (g/dl), pre-HD
plasma atrial natriuretic peptide (ANP, pg/ml) level,
brain natriuretic peptide (BNP, pg/ml) level, and findings
on pre-HD electrocardiograms (ECGs) were obtained.
CVD was defined as myocardial infarction, heart failure,
arrhythmia, cerebral hemorrhage, and brain infarction.
The primary endpoint was all-cause mortality, and the
secondary was cardiovascular mortality. Hypertension
was defined as a condition (1) requiring the use of the
following types of antihypertensive drug: calcium channel
blockers, angiotensin-converting enzyme inhibitors, angio-
tensin receptor blockers, and beta blockers or (2) having
pre-HD hypertension (systolic blood pressure 160 mmHg
or higher, diastolic blood pressure 100 mmHg, or higher).
Hypotension during HD was defined as a condition requir-
ing the use of using the following medicines during HD:
amezinium metilsulfate, droxidopa, etilefrine hydrochloride,
midodrine hydrochloride, rapid infusion of normal saline,
and an injection of 10 % saline or 50 % glucose solution.
Abnormal findings on ECGs were (1) a horizontal ST
segment depression of more than 1 mm or a negative T
wave, (2) an abnormal Q wave, and (3) atrial fibrillation.
The number of abnormal findings was used as the ECG
score (0 to 3).Follow-up
Patients were prospectively followed up at the same clinics
or hospitals. The data on mortality were examined by ana-
lyzing medical records from the outpatient clinic and con-
ducting telephone interviews with the patients or their
families. The data base was implemented in February
2014, with prospective data collection on all patients. At
the end of December 2014, data were fixed and collected
at the data center and analyzed independently of the par-
ticipating investigator.
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Variables are expressed as mean ± standard deviation.
For variables not normally distributed, natural logarithm
values were considered, i.e., the natural logarithm values
of vintage [ln(vintage)]. Intergroup comparisons of pa-
rameters were performed using chi-square test, t test,
and Mann-Whitney U test as appropriate. Age was
scored into two categories (older): 0, less than 65 years;
1, 65 years or more. BMI was categorized into two
values (low BMI): 1, less than 20.4 kg/m2 (median); 0,
20.4 kg/m2 or more. Controlled hemoglobin level was
scored as 0 (10 to 12 g/dl) and 1 (other levels). Pre-HD
CTR was categorized into two values (high CTR) based
on the Japanese Society for Dialysis Therapy Guidelines
for Management of Cardiovascular Diseases in Patients
on Chronic Hemodialysis: 0, less than 50 %; 1, 50 % or
higher. Pre-HD plasma ANP level was categorized into
two values (high ANP level): 0, less than 132.5 pg/mL; 1,
132.5 pg/mL or higher. Pre-HD plasma BNP level was
categorized into two values (high BNP level): 0, less than
250 pg/mL; 1, 250 pg/mL or higher. The cutoff values of
pre-HD plasma ANP and BNP levels were determined
by sensitivity analysis. In statistical analysis, because the
number of the patients with ECG score of 3 was small,
patients with an ECG score = 3 were treated as having
ECG score = 2. The primary outcome was all-cause death
within 15 years. The other outcomes evaluated were as
follows: all-cause death within 10 and 5 years and
CVD-caused death within 15, 10, and 5 years.
Step 1: (1) Each candidate variable for a risk scoring
model was selected from the development dataset using
each of the Cox proportional hazard models (PHMs).
Candidate Cox PHMs for the risk scoring model were
constructed using the hierarchical backward elimination
procedure. The initial multivariate Cox PHM was con-
structed including the selected variables. When variables
were not statistically significant in the model, the variables
were deleted and the next models were constructed until
all variables were statistically significant (p < 0.05). (2) To
develop a risk scoring model, we assigned each variable in
the final model a weighted score proportional to the smal-
lest parameter estimate, which was rounded to the nearest
integer. For example, a point of a variable was the param-
eter estimate of the variable divided by the smallest par-
ameter estimate in the final model. For each patient, the
risk score was calculated using the risk scoring model as
the sum of the points. (3) On the basis of the categorical
criteria of the risk score, the patients were divided into
four groups using Kaplan Meier survival curves (groups 1
to 4). Then, the survival curve of each group was evalu-
ated on the basis of Kaplan Meier survival curves. Cox
PHMs were used to compare the risk of the outcome
between the groups. Cox PHMs were adjusted for the
variables that were not included in the final model, suchas gender, ln(vintage), controlled hemoglobin level, and
high ANP level. The results are presented here as hazard
ratios (HR) with 95 % confidence interval (CI).
Step 2: The risk score was calculated for each patient
using the validation dataset. On the basis of the categor-
ical criteria of the risk score, patients were divided into
four groups. Patients’ survival curves were evaluated by
Kaplan Meier analysis. The risk of the outcome was com-
pared between the groups using Cox PHMs adjusted for
gender, ln(vintage), controlled hemoglobin level, and high
ANP level. These analyses were conducted using SAS ver-
sion 9.4 (SAS, Inc., NC, USA). Statistical significance was
defined as p < 0.05.Results
The study population consisted of 622 patients. The mean
duration of dialysis of the patients was 5.0 ± 6.0 years
(range, 0.1 to 32.0 years). The primary etiology of renal
disease in these patients was chronic glomerulonephritis
in 255 patients (35.2 %), diabetic nephropathy in 197
(27.2 %), nephrosclerosis in 72 (9.9 %), IgA nephritis in 31
(4.2 %), polycystic renal disease in 24 (3.3 %), and other
diseases in 145 (20.0 %). There were 217 patients (30.0 %)
with DM at the time of study registration. At baseline,
medical therapy included calcium antagonists in 411 pa-
tients (56.7 %), angiotensin-converting enzyme inhibitors
and/or angiotensin-II receptor blockers in 129 (17.8 %),
nitrates in 137 (18.9 %), digoxin in 48 (6.6 %), and beta
blockers in 36 (4.9 %) in varying combinations.
After randomization, 312 patients were included for
obtaining data for the development dataset and 310 pa-
tients for obtaining those for the validation dataset
(Fig. 1). Their demographics including biochemical data
are shown in Table 1. CTR, plasma BNP level, the num-
ber of the patients with high BNP level, and the numbers
of all-cause death and CVD-caused death within 15 and
10 years in the validation dataset were higher than those
in the development dataset.Development and categorization of risk score
After the selection of the variables, the initial model was
constructed. Ln(vintage) and controlled hemoglobin level
were not included in the model: ln(vintage), p = 0.35;
controlled hemoglobin level, p = 0.43. The initial model
included the following variables: gender, older, DM, his-
tory of CVD, hypotension, high CTR, high ANP level,
high BNP level, and ECG score. However, in the initial
model, gender, low BMI, history of CVD, and high ANP
level were not statistically significant: gender, p = 0.74;
low BMI, p = 0.25; history of CVD, p = 0.69; high ANP
level, p = 0.99. Then, the final model included older,
DM, hypotension, high CTR, high BNP level, and ECG
score.
Table 1 Baseline characteristics
All Development dataset Validation dataset P value
N 622 312 310
Male (%) 376 (60.45) 191 (61.22) 185 (59.68) 0.69
Age (years) 52.9 ± 14.1 51.9 ± 14.3 53.9 ± 14.0 0.07
Older (%) 133 (22.09) 63 (20.19) 70 (22.58) 0.47
Vintage (years) 5.7 ± 6.0 5.6 ± 5.7 5.9 ± 6.3 0.84
3.4 (1.2, 8.0) 3.5 (1.2, 7.8) 3.3 (1.3, 8.3)
BMI (kg/m2) 20.7 ± 2.7 20.6 ± 2.7 20.7 ± 2.8 0.83
Low BMI (%) 290 (46.62) 146 (46.79) 144 (46.45) 0.93
DM (%) 170 (27.33) 78 (25) 92 (29.68) 0.19
History of CVD 72 (11.58) 35 (11.22) 37 (11.94) 0.78
Hypertension 619 (99.52) 310 (99.36) 309 (99.68) 0.57
Pre-HD hypertension 619 (99.52) 310 (99.36) 309 (99.68) 0.57
Antihypertensive drug use 378 (60.77) 196 (62.82) 182 (58.71) 0.29
Hypotension during HD 218 (35.05) 105 (33.65) 113 (36.45) 0.46
CTR (%) 50.7 ± 5.0 50.2 ± 5.1 51.2 ± 5.0 0.02
High CTR (%) 330 (53.05) 155 (49.68) 175 (56.45) 0.09
Hemoglobin level (g/dL) 9.5 ± 1.1 9.4 ± 1.0 9.6 ± 1.2 0.07
Controlled hemoglobin level (%) 189 (30.39) 87 (27.88) 102 (32.9) 0.17
Plasma ANP level (pg/mL) 182.4 ± 153.2 180.0 ± 170.8 184.8 ± 133.5 0.10
143 (87.4, 238) 132.5 (79.9, 230.0) 149.5 (91.6, 241.0)
High ANP level (%) 472 (75.88) 231 (74.04) 241 (77.74) 0.28
Plasma BNP level (pg/mL) 474.4 ± 613.4 470.2 ± 699.3 478.6 ± 513.7 0.04
291.5 (150, 587) 261.5 (131.0, 508.0) 335.0 (166.0, 614.0)
High BNP level (%) 477 (76.69) 227 (72.76) 250 (80.65) 0.02
ST segment depression or negative T wave (%) 221 (35.53) 108 (34.62) 113 (36.45) 0.63
Abnormal Q wave (%) 39 (6.27) 20 (6.41) 19 (6.13) 0.89
Atrial fibrillation (%) 14 (2.25) 4 (1.28) 10 (3.23) 0.10
ECG score (%) 0.59
0 380 (61.09) 195 (62.5) 185 (59.68)
1 211 (33.92) 103 (33.01) 108 (34.84)
2 30 (4.82) 13 (4.17) 17 (5.48)
3 1 (0.16) 1 (0.32) 0 (0)
All-cause death within 15 years (%) 409 (65.76) 200 (64.1) 209 (73.87) 0.01
All-cause death within 10 years (%) 342 (54.98) 155 (49.68) 187 (60.32) 0.01
All-cause death within 5 years (%) 197 (31.67) 96 (30.77) 101 (32.58) 0.63
CVD-caused death within 15 years (%) 230 (36.98) 102 (32.69) 128 (55.65) 0.03
CVD-caused death within 10 years (%) 197 (31.67) 86 (27.56) 111 (35.81) 0.03
CVD-caused death within 5 years (%) 117 (18.81) 56 (17.95) 59 (19.03) 0.73
Follow-up period (days) 2963.4 ± 1839.3 3043.7 ± 1904.8 2882.5 ± 1770.5 0.28
2813 (1301, 5040) 2908 (1246, 5182) 2712 (1319, 4584)
Variables are expressed as mean ± standard deviation. Vintage, plasma ANP and BNP levels, and follow-up days are also shown as median and interquartile range.
Intergroup comparisons of parameters were performed using chi-square test, t test, and Mann Whitney U test as appropriate as appropriate
Development dataset dataset for the development of risk score, Validation dataset dataset for the validation of risk score, Older 65 ≤ age, BMI body mass index, Low
BMI BMI <20.4 kg/m2, DM diabetes mellitus as a cause of end-stage renal disease, CVD cardiovascular disease, HD hemodialysis, CTR cardiothoracic ratio, High CTR
50 % ≤ CTR, ANP atrial natriuretic peptide, High ANP level 132.5 pg/mL ≤ plasma ANP level, BNP brain natriuretic peptide, High BNP level 250 pg/mL ≤ plasma BNP
level, ECG score the number of abnormal findings in electrocardiogram
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Fig. 2 Association between groups and mortality in development
dataset. Kaplan Meier survival curves showed that group 1 had the
highest survival probability
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ameter estimates in the final model as follows (Table 2):
Risk score ¼ older þ DM þ hypotension
þ high CTR þ high BNP level
þ ECG score
Older, yes = 3, no = 0; DM, yes = 3, no = 0; hypotension,
yes = 1, no = 0; high CTR, yes = 1, no = 0; high BNP level,
yes = 1, no = 0; ECG score, score 0 = 0, score 1 = 1, score
2 = 5.
The Kaplan Meier survival curves showed a significant
difference in the survival probability of the patients de-
termined on the basis of risk score (log-rank test p =
0.0001). The patients were categorized into four groups
on the basis of the risk score: group 1 (low risk), risk
score = 0; group 2, score = 1 to 3; group 3, score = 4 to 5;
and group 4 (high risk), score = 6 and higher. The Kaplan
Meier survival curve showed the difference in the survival
probability of the groups (log-rank test p = 0.0001) (Fig. 2).
Groups 2 to 4 showed higher risks of all-cause death than
group 1: group 2, HR 4.29 95 % CI (2.29, 8.03), adjusted
HR 4.19 95 % CI (2.22, 7.91); group 3, HR 14.47 95 % CI
(7.55, 27.72), adjusted HR 14.68 95 % CI (7.58, 28.41);
group 4, HR 21.84 95 % CI (10.96, 43.53), adjusted HR
24.29 95 % CI (11.83, 49.89).
Validation of risk score and its categories
Using the validation dataset, we compared the risk of
death between the groups. The risks of all-cause death
and CVD-caused death in group 4 were higher than those
in other groups (Table 3). The Kaplan Meier survival
curves for all-cause death and CVD-caused death showed
a lower survival probability in group 4 than in the other
groups for 15 years (Fig. 3). Moreover, groups 2 to 4
showed high risks of all-cause death and CVD-caused
death than group 1 (Table 4).Table 2 Parameter estimates in the final models and risk score
Variables Parameter estimate in the final model Ratio Score
Older 0.96 2.97 3
DM 0.85 2.63 3
Hypotension 0.41 1.25 1
High CTR 0.38 1.16 1
High BNP level 0.32 1 1
ECG score = 1 0.46 1.43 1
ECG score = 2 1.52 4.69 5
Each parameter estimate in the final models was compared with the smallest
parameter estimate (High BNP level). Then, the risk scores were determined.
Older 65 ≤ age, DM diabetes mellitus as a cause of end-stage renal disease,
Hypotension hypotension during hemodialysis, High CTR 50 % ≤ cardiothoracic
ratio, High BNP level 250 pg/mL ≤ plasma brain natriuretic peptide level, ECG
score the number of abnormal findings in electrocardiogramDiscussion
Although the prognosis of the HD patients in Japan is
relatively good compared with that in other countries,
the leading cause of death is also cardiovascular disease
[2]. Several reports have been published that disclosed
the usefulness of particular factors related to cardiovas-
cular disorder for predicting a HD patient’s prognosis.
Such factors are coronary artery disease [5], hypertension
[6], left ventricular hypertrophy [7], hypotension [8], left
ventricular function [9], left ventricular size [10], BNP
level [11], atrial fibrillation [12], hypocholesterolemia [13],
cardiac troponin [14], C-reactive protein level [15], and
autonomic nervous system abnormality [16] among
others. However, it has never been considered the contri-
bution rate of each factor for the mortality of patients on
maintenance HD. Moreover, there was no report on the
scoring system for predicting the long-term prognosis in
those patients, considering that the vintage of dialysis pa-
tients has been increasing with a quarter of them receiving
HD more than 10 years in Japan [2]. In this study, we pro-
posed a scoring system using routine measurements to
predict the long-term prognosis of HD patients.
We evaluated the patients’ basic information, such as
age, gender, physical constitution, DM as a cause of ESRD,
and history of CVD, which appears in the very first page
of the patients’ chart. Chest X-ray images and ECGs are
obtained routinely, and hemoglobin and natriuretic pep-
tide levels are also frequently measured at the beginning
of a regular HD session. Blood pressure is routinely
measured during HD to ensure safe treatment. In this
study, we focused on these common parameters that
are obtained routinely at the beginning of maintenance
HD and during maintenance HD treatment.
As a result, most of the significant parameters listed in
this study were found to be related to cardiac and/or cir-
culatory disorders. DM is a strong risk factor for athero-
sclerosis, and abnormal Q wave and ST depression are
signs of coronary artery disease. High BNP level, high
CTR, and hypotension during HD treatment are mainly
Table 3 Risks of death in groups on the basis of risk scores in validation dataset
Follow-up period 15 years 10 years 5 years
All-cause death
Group 1 0.15 (0.06, 0.25) 0.14 (0.042, 0.23) 0.039 (0.001, 0.091)
Group 2 0.58 (0.50, 0.67) 0.42 (0.34, 0.51) 0.23 (0.16, 0.30)
Group 3 0.92 (0.86, 0.99) 0.74 (0.64, 0.85) 0.49 (0.36, 0.61)
Group 4 0.98 (0.93, 0.99) 0.93 (0.84, 0.99) 0.65 (0.50, 0.80)
CVD-caused death
Group 1 0.12 (0.029, 0.20) 0.096 (0.016, 0.18) 0.019 (0.001, 0.057)
Group 2 0.26 (0.18, 0.33) 0.21 (0.14, 0.28) 0.088 (0.040, 0.14)
Group 3 0.55 (0.43, 0.67) 0.50 (0.38, 0.62) 0.32 (0.21, 0.43)
Group 4 0.60 (0.45, 0.75) 0.58 (0.42, 0.73) 0.40 (0.25, 0.55)
Values are risks of death with 95 % confidence intervals in each group. Patients were categorized into four groups on the basis of their risk scores
CVD cardiovascular disease
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hemodynamics. Shoji et al. reported that hypotension
during HD treatment, which is a significant prognostic
parameter, is closely related to interdialysis body weight
gain beside age and vintage [8]. This condition is consid-
ered to suggest a chronic volume overload and an acute
change in loading condition caused by HD treatment.
Heart failure, DM, and aging are also risk factors for
arrhythmias. Regarding the cardiac arrhythmia in HD
patients, ventricular arrhythmia was focused on as a pos-
sible to cause cardiac death [17]. Although the incidence
and severity of ventricular premature beats were high,
there was no direct evidence that ventricular arrhythmia
itself is related to the prognosis in these patients. It has
been documented that atrial fibrillation affects the prog-
nosis in non-ESRD patients [18] and its prevalence in-
creases with aging [19]. Atrial fibrillation is much more
frequent in HD patients than in the general population;
age, HD vintage, presence of some heart diseases, and
left atrial dilatation are associated with the arrhythmia
[20]. Va’zquez et al. reported that atrial fibrillation itself
worsen the prognosis of HD patients [12].Fig. 3 Association between groups and mortality in validation dataset. Kap
probability free from all-cause death (a) and CVD-caused death (b). CVD caWe developed a scoring system for predicting the
long-term prognosis of chronic HD patient using these
parameters. In Japan, the same set of examinations is
commonly performed in all the HD patients routinely in
many facilities. This scoring system provides us proper
usage of medical resources in the medical care of ESRD.
The scoring system has several features. First, the scoring
system we developed in this study includes markers com-
monly used to evaluate cardiac disease, which were easily
measurable and did not require special skills of examiners.
Moreover, the scoring system can be used to evaluate HD
patients’ long-term prognosis. Previous scores were de-
veloped to evaluate HD patients’ short-term mortality
[21, 22]. These scores can be used separately. For exam-
ination, the scoring system of this study is used to evaluate
a HD patient’s long-term prognosis. If the patient has a
high risk of death, his prognosis will be evaluated using a
score for short-term prognosis, which can exactly predict
his prognosis. HD patients’ prognosis is determined by
many factors. The scores were differently developed on
the basis of the population and purpose. Because a sin-
gle score cannot cover all of the patients with manylan Meier survival curves showed that group 1 had the highest survival
rdiovascular disease
Table 4 Groups with high risk scores and high risks of death
Follow-up period 15 years 10 years 5 years
All-cause death HR (95 % CI) aHR (95 % CI) HR (95 % CI) aHR (95 % CI) HR (95 % CI) aHR (95 % CI)
Group 1 Reference Reference Reference Reference Reference Reference
Group 2 4.66 (2.25, 9.64) 4.56 (2.20, 9.49) 3.48 (1.59, 7.62) 3.23 (1.47, 7.10) 6.43 (1.54, 26.80) 5.71 (1.36, 23.92)
Group 3 13.62 (6.48, 28.63) 15.23 (7.17, 32.34) 9.41 (4.25, 20.80 10.06 (4.50, 22.48) 16.89 (4.05, 70.44) 17.29 (4.11, 72.65)
Group 4 20.86 (9.60, 45.31) 24.96 (11.21, 55.59) 14.79 6.56, 33.34) 17.02 (7.36, 39.33) 24.761 (5.88, 104.34) 25.25 (5.89, 108.23)
CVD-caused death HR (95 % CI) aHR (95 % CI) HR (95 % CI) aHR (95 % CI) HR (95 % CI) aHR (95 % CI)
Group 1 Reference Reference Reference Reference Reference Reference
Group 2 2.59 (1.09, 6.17) 2.51 (1.05, 6.01) 2.45 (0.95, 6.34) 2.32 (0.89, 6.03) 4.84 (0.63, 37.21) 4.61 (0.60, 35.58)
Group 3 9.62 (4.03, 22.96) 10.79 (4.45, 26.17) 9.20 (3.58, 23.62) 10.17 (3.90, 26.49) 22.26 (2.99, 165.50) 25.89 (3.45, 194.30)
Group 4 14.78 (5.95, 36.74) 19.06 (7.36, 49.31) 13.70 (5.17, 36.32) 17.27 (6.27, 47.54) 30.66 (4.06, 231.34) 37.71 (4.87, 291.93)
Values are HRs with 95 % CIs of all groups compared with group 1. Groups 2 to 4 show higher risks of death than group 1. Patients were categorized into four
groups on the basis of their risk scores
CVD cardiovascular disease, HR hazard ratio, aHR adjusted hazard ratio, CI confidence interval
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basis of a patient’s condition.
This study has several limitations. First, we were un-
able to examine the patients with missing data in this
study, which might have caused selection bias. Second,
the dataset did not include sufficient data for assessing
nutrition, chronic kidney disease—mineral and bone dis-
order, comorbid conditions, and medications. Clinical
practice guidelines for the management in hemodialysis
patients established by the Japanese Society for Dialysis
Therapy have been implemented since 2004. Although
the markers in this study were selected in 1997, they are
still commonly used. Third, although we developed and
validated the risk scoring system using the different
datasets, the population of the present study cannot be
said to represent the HD patients in Japan. And there
were differences in the characteristics of the development
dataset and validation datasets such as the numbers of
all-cause death and CVD-caused death. The differences
might cause bias for the risk score. However, the valid-
ation of the scoring system showed a possibility that
the scoring system was applicable to a population with
different risk. Further validation study is required.
Fourth, we used dichotomized variables. Although this
strategy simplifies the development of a risk scoring
system, the use of continuous variables may provide
more refined information [21]. Fifth, this study was car-
ried out from 1997 to 2014. During this period, various
new medicines were developed such as angiotensin II
receptor blockers and erythropoiesis-stimulating agents.
Moreover, various guidelines were established by the
Japanese Society for Dialysis Therapy. We were unable
to time-dependently evaluate the effects of these inno-
vations on the prognosis of the subjects. This might
have made bias on this scoring system, however, because
the scoring system did not include medications and all of
the subjects had equal opportunity to benefit from theseinnovations. The effects of bias might be reduced, and
the categorization of the subjects from high-risk group
to low-risk group may have minimized errors.
Conclusions
In conclusion, this study shows the significant association
between long-term prognosis and cardiovascular disease-
related risk factors in HD patients and we developed and
validated a new simple scoring system for predicting their
prognosis spanning long periods of time. This will also
contribute not only to the grading of the risk of HD pa-
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